OTCMKTS:CYBN Cybin (CYBN) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free CYBN Stock Alerts $0.36 -0.01 (-2.74%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$0.35▼$0.3650-Day Range$0.32▼$0.4652-Week Range$0.21▼$0.74Volume3.05 million shsAverage Volume5.14 million shsMarket Capitalization$145.85 millionP/E RatioN/ADividend YieldN/APrice Target$7.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesOwnershipSEC FilingsStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesOwnershipSEC Filings Get Cybin alerts: Email Address Cybin MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside2,012.7% Upside$7.50 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.19) to ($0.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.95 out of 5 stars 3.5 Analyst's Opinion Consensus RatingCybin has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCybin has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for CYBN. Previous Next 0.0 Dividend Strength Dividend YieldCybin does not currently pay a dividend.Dividend GrowthCybin does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CYBN. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Cybin this week, compared to 1 article on an average week.Search InterestOnly 25 people have searched for CYBN on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat Follows19 people have added Cybin to their MarketBeat watchlist in the last 30 days. This is an increase of 6% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cybin insiders have not sold or bought any company stock.Percentage Held by Insiders15.00% of the stock of Cybin is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 17.94% of the stock of Cybin is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cybin are expected to grow in the coming year, from ($0.19) to ($0.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cybin is -1.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cybin is -1.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCybin has a P/B Ratio of 1.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Cybin Stock (OTCMKTS:CYBN)Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.Read More CYBN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYBN Stock News HeadlinesApril 19, 2024 | americanbankingnews.comCybin (OTCMKTS:CYBN) Stock Price Down 2%April 18, 2024 | businesswire.comCybin Announces Publication of Research Manuscript in the Journal of Medicinal ChemistryApril 24, 2024 | Crypto Swap Profits (Ad)He Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.April 16, 2024 | businesswire.comCybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive DisorderApril 10, 2024 | businesswire.comCybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 10, 2024 | businesswire.comCybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceMarch 26, 2024 | investorplace.com3 Penny Stocks That Could Be Multibaggers in the Making: March EditionMarch 19, 2024 | businesswire.comCybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 MillionApril 24, 2024 | Crypto Swap Profits (Ad)He Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.March 18, 2024 | businesswire.comCybin to Present at Public Ventures Discovery Day on March 19th in DallasMarch 15, 2024 | businesswire.comCybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety DisorderMarch 14, 2024 | markets.businessinsider.comCybin’s CYB003 Shows Promise in MDD Treatment, Justifying Buy RatingMarch 14, 2024 | msn.comCybin to begin Phase 3 study for psychedelic drug mid-yearMarch 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cybin on Promising CYB003 Clinical Data and Strategic FDA DesignationsMarch 14, 2024 | businesswire.comCybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program DesignMarch 13, 2024 | markets.businessinsider.comCybin Gets Breakthrough Therapy Designation For Its Psychedelic-based Therapeutic CYB003March 13, 2024 | businesswire.comCybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive DisorderMarch 12, 2024 | businesswire.comCybin to Host Conference Call and Webcast to Provide Program Update for CYB003March 10, 2024 | investorplace.com3 High-Potential Penny Stocks to Turn $1000 into $1 millionFebruary 27, 2024 | businesswire.comCybin to Present at the TD Cowen 44th Annual Health Care ConferenceFebruary 16, 2024 | thestreet.comCybin Inc.February 14, 2024 | finance.yahoo.comCybin Reports Third Quarter Financial Results and Recent Business HighlightsFebruary 14, 2024 | businesswire.comCybin Reports Third Quarter Financial Results and Recent Business HighlightsFebruary 7, 2024 | finance.yahoo.comCybin Announces Grant of Two Additional Patents in Japan in Support of its DMT ProgramJanuary 23, 2024 | msn.comFDA Green Lights Cybin's Psychedelic Clinical Study Assessing Generalized AnxietyJanuary 23, 2024 | msn.comCybin gets FDA clearance for Phase 2a study of psychedelic drugJanuary 23, 2024 | finance.yahoo.comCybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety DisorderSee More Headlines Receive CYBN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cybin and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today4/24/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:CYBN CUSIPN/A CIK1833141 Webwww.cybin.com Phone(866) 292-4601FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$7.50 High Stock Price Target$10.00 Low Stock Price Target$5.00 Potential Upside/Downside+2,012.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,930,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-93.17% Return on Assets-84.68% Debt Debt-to-Equity RatioN/A Current Ratio2.61 Quick Ratio2.61 Sales & Book Value Annual Sales$680,000.00 Price / Sales214.49 Cash FlowN/A Price / Cash FlowN/A Book Value$0.19 per share Price / Book1.87Miscellaneous Outstanding Shares410,855,000Free Float170,213,000Market Cap$145.85 million OptionableNot Optionable Beta0.43 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Eric So L.L.B. (Age 48)Co-Founder, President & Executive Chairman Comp: $459.43kMr. Douglas L. Drysdale (Age 54)Chief Executive Officer Comp: $614.17kMr. Paul Glavine (Age 35)Co-Founder, Chief Growth Officer & Director Comp: $459.43kMr. Greg Cavers (Age 53)Chief Financial Officer Comp: $242.38kMr. Aaron BartloneChief Operating OfficerMr. John Kanakis (Age 44)Co-Founder Comp: $704.87kDr. Alex L. Nivorozhkin Ph.D. (Age 64)Chief Scientific Officer Ms. Lori ChallengerChief Compliance, Ethics & Administrative OfficerMr. Gabriel Fahel (Age 48)Chief Legal Officer & Corporate Secretary Sara Brittany SomersetChief Communications OfficersMore ExecutivesKey CompetitorsNGM BiopharmaceuticalsNASDAQ:NGMKinnate BiopharmaNASDAQ:KNTEBiopharmxNYSEAMERICAN:BPMXNervGen PharmaOTCMKTS:NGENFAmpliphi BiosciencesNYSEAMERICAN:APHBView All CompetitorsInstitutional OwnershipThrive Wealth Management LLCSold 45,300 shares on 4/16/2024Ownership: 0.020%View All Institutional Transactions CYBN Stock Analysis - Frequently Asked Questions Should I buy or sell Cybin stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cybin in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CYBN shares. View CYBN analyst ratings or view top-rated stocks. What is Cybin's stock price target for 2024? 2 Wall Street analysts have issued 12 month target prices for Cybin's shares. Their CYBN share price targets range from $5.00 to $10.00. On average, they anticipate the company's stock price to reach $7.50 in the next year. This suggests a possible upside of 2,012.7% from the stock's current price. View analysts price targets for CYBN or view top-rated stocks among Wall Street analysts. How have CYBN shares performed in 2024? Cybin's stock was trading at $0.41 at the start of the year. Since then, CYBN stock has decreased by 13.4% and is now trading at $0.3550. View the best growth stocks for 2024 here. How were Cybin's earnings last quarter? Cybin Inc. (OTCMKTS:CYBN) posted its earnings results on Wednesday, February, 14th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.03) by $0.04. Who are Cybin's major shareholders? Cybin's stock is owned by a number of retail and institutional investors. Top institutional investors include Thrive Wealth Management LLC (0.02%). How do I buy shares of Cybin? Shares of CYBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CYBN) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingNew Trump BombshellThe Freeport SocietyThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
